Grapiprant is a new active ingredient under development for the control of pain and inflammation.
A validated HPLC method with spectrofluorimetric detection has been developed.
The chromatographic runs were specific with no interfering peaks at the retention times of the analyte and IS.
LOD and LLOQ were 3 and 10 ng/mL.
This method is suitable for pharmacokinetic investigations such as guiding dose adjustment.